These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8665427)

  • 21. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.
    Collins P; Rosano G; Casey C; Daly C; Gambacciani M; Hadji P; Kaaja R; Mikkola T; Palacios S; Preston R; Simon T; Stevenson J; Stramba-Badiale M
    Climacteric; 2007 Dec; 10(6):508-26. PubMed ID: 18049944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing cardiovascular risk in menopausal women.
    Rosano GM; Vitale C; Tulli A
    Climacteric; 2006 Sep; 9 Suppl 1():19-27. PubMed ID: 16899440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
    Fodor JG; Whitmore B; Leenen F; Larochelle P
    CMAJ; 1999 May; 160(9 Suppl):S29-34. PubMed ID: 10333851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of postmenopausal hormone therapy on cardiovascular risk.
    Rossouw JE
    J Hypertens Suppl; 2002 May; 20(2):S62-5. PubMed ID: 12183856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sex steroid hormones on lipoprotein levels in pre- and post menopausal women.
    Knopp RH
    Can J Cardiol; 1990 May; 6 Suppl B():31B-35B. PubMed ID: 2188717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart disease in women.
    Barrett-Connor E
    Fertil Steril; 1994 Dec; 62(6 Suppl 2):127S-132S. PubMed ID: 7958006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex hormones and the cardiovascular system: effects on arterial function in women.
    Teede HJ
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):672-6. PubMed ID: 17581228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones.
    Rossouw JE
    Maturitas; 2005 May; 51(1):51-63. PubMed ID: 15883110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy and cardiovascular disease revisited.
    Stevenson JC
    Menopause Int; 2009 Jun; 15(2):55-7. PubMed ID: 19465669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
    Campbell NR; Ashley MJ; Carruthers SG; Lacourcière Y; McKay DW
    CMAJ; 1999 May; 160(9 Suppl):S13-20. PubMed ID: 10333849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S
    Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.